-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Presidential Symposium

Program: General Sessions
Tuesday, December 14, 2021: 11:00 AM-12:30 PM
Hall C2-C3 (Georgia World Congress Center)

Lecture Title:
Dawn of a New Era: Targeting p53 Mutant Hematologic Malignancies

Chair:
Martin S. Tallman, MD, Memorial Sloan-Kettering Cancer Center
Disclosures:
Tallman: Oncolyze: Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Biosight: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Innate Pharma: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Kura: Membership on an entity's Board of Directors or advisory committees; NYU Grand Rounds: Honoraria; Mayo Clinic: Honoraria; UC DAVIS: Honoraria; Northwell Grand Rounds: Honoraria; NYU Grand Rounds: Honoraria; Danbury Hospital Tumor Board: Honoraria; Acute Leukemia Forum: Honoraria; Miami Leukemia Symposium: Honoraria; KAHR: Membership on an entity's Board of Directors or advisory committees; Orsenix: Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Amgen: Research Funding; Rafael Pharmaceuticals: Research Funding; Glycomimetics: Research Funding; Biosight: Research Funding; Orsenix: Research Funding; Abbvie: Research Funding; New Orleans Cancer Symposium: Honoraria; ASH: Honoraria; NCCN: Honoraria.
The tumor suppressor gene p53 is located on chromosome 17 and has an important role in the development of a wide variety of human malignancies. p53 contributes to the normal cascade of events which inhibit tumor formation. However, it is the most frequently mutated gene in human malignancy. Mutations in p53 perturb this series of molecular changes, inhibit the suppressor function of p53, and lead to malignant cell proliferation. Therefore, drug discovery in an effort to target mutant p53 and restore normal p53 function has been an exciting focus of current research. The three presentations will cover a wide range of topics including the basic biology of the p53 gene, drug discovery to target mutant p53 and current therapeutic approaches for p53 mutant hematologic malignancies. 

Dr. Carol Prives will discuss the basic structure and function of the normal and mutated p53 gene and the complex series of molecular events leading to tumor suppression and its inhibition.

Dr. Guillermina Lozano will discuss mechanisms of tumor cell addiction to mutant p53 and therapeutic opportunities.

Dr. Matthew Davids will discuss current therapeutic strategies to inhibit or reactivate mutant p53 and its pathway in both acute and chronic hematologic malignancies now that a number of active agents are available.

Carol Prives, PhD

Columbia University, New York, NY

Guillermina Lozano, PhD

Genetics, University of Texas M.D. Anderson Cancer Center, Houston, TX

Matthew S. Davids, MD

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

See more of: General Sessions